Technology
PharmaEssentia has developed a novel pegylation technology platform designed to realize the therapeutic potential of interferons for treating various cancers, including myeloproliferative neoplasms (MPNs).
Interferons are among the most recognized and well-studied therapeutic agents for a range of serious diseases. These proteins help the immune system fight certain infections, diseases, and cancers. However, historically, use of interferons in treating MPNs and other diseases has been limited due to difficulties with administration and tolerability. In addition to IFN, we are developing new cytokine therapies leveraging our proprietary pegylation technology with the potential to be best-in-class.
PharmaEssentia has worked to address these shortcomings with a proprietary PEGylation technology, with the goal of giving physicians new and improved therapeutic options.
Leveraging pioneering expertise in interferons, our Research and Development team developed an innovative PEGylation technology designed to improve tolerability, ease of administration, and efficacy in MPNs. This led to the successful development of ropeginterferon alfa-2b (P1101), a mono-pegylated proline interferon.
Our proprietary, site-specific PEGylation technology has the potential to provide long-lasting biologics applicable for a wide array of indications.
Our research and development teams have extensive capabilities in analytical science, chemistry, cell culture, protein engineering, pharmaceutical science, and process development. Our R&D facilities in Taiwan and the PharmaEssentia Innovation Research Center (PIRC) in the U.S. form a global innovation bridge that accelerates research and development across borders. We also have strong partnerships with world-class collaborators, including university research institutes and biotechnology and pharmaceutical companies.
Visit The PharmaEssentia Innovation Research Center (PIRC) Website
PharmaEssentia’s clinical pipeline includes candidates with a focus across a range of MPNs and other hematologic malignancies. We intend to expand into other areas where our innovative technology can address needs and support improved outcomes.
Our R&D identifies and advances scientific breakthroughs that make new therapies for rare cancers possible, helping to improve patients’ health and quality of life. We’re currently focused on three main areas of drug discovery:
Developing best-in-class PEGylated cytokines across multiple indications, starting with hematology, oncology, and immunology.
Investigating new modalities that target novel checkpoint receptors that regulate the immune responses relevant to oncology and immunology.
Our in-house expertise in antibody discovery and protein conjugation technology uniquely positions us to discover novel, innovative ADCs for cancer treatment.
Erik Sampson
Director of Translational Pharmacology
